BioSpace News Archive

Brii Biosciences Limited announced topline cohort-level unblinded Week 24 and Week 36 data from interim analysis of a randomized, placebo-controlled and double-blinded Phase 2 study of BRII-179, a first-in-class Pre-S1/Pre-S2/S therapeutic vaccine, in combination treatment with pegylated interferon-alpha in patients with chronic hepatitis B compared with PEG-IFNα only treatment.

Guangzhou Gloria Biosciences announced that its fully human anti-PD-1 monoclonal antibody, Zimberelimab injection has received marketing approval from the China National Medical Products Administration, as monotherapy for the treatment of recurrent or metastatic cervical cancer patients with positive PD-L1 expression who progressed on or after platinum-based chemotherapy.

SpliSense announced that it has successfully completed a first-in-human, Phase 1 clinical trial of SPL84, the Company’s lead inhaled anti sense oligonucleotide product for the treatment of patients with CF carrying the 3849+10 kilobase C->T splicing mutation in the transmembrane conductance regulator gene.

Viking Therapeutics, Inc. announced the initiation of a Phase 2 clinical trial of VK2735, the company’s wholly-owned dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors.

Allay Therapeutics announced the appointment of Nicole Vitullo, venture partner at Arboretum Ventures, to its board of directors.

Nimbus Therapeutics, LLC announced the closing of a $210 million private financing to advance its next wave of tech-enabled small molecule medicines.

Quince Therapeutics, Inc., a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients’ lives, announced the appointment of Charles S. Ryan, J.D., Ph.D. as President.

Castle Biosciences, Inc., a company improving health through innovative tests that guide patient care, will share a poster detailing new data regarding the Company’s IDgenetix® test at the upcoming Psych Congress 2023 conference, being held in Nashville, Tennessee, Sept. 6-10.

GlycoMimetics, Inc. announced dosing of the first cohort of healthy volunteers in a Phase 1a study of GMI-1687 to evaluate safety, tolerability, and pharmacokinetics.

Silence Therapeutics plc announced that Company management will participate in the following investor conferences and invited investors to participate by webcast.